Edition:
United States

Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

8.10USD
23 May 2017
Change (% chg)

$0.05 (+0.62%)
Prev Close
$8.05
Open
$8.10
Day's High
$8.15
Day's Low
$7.90
Volume
121,428
Avg. Vol
333,160
52-wk High
$14.60
52-wk Low
$5.50

STML.O

Chart for STML.O

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.13
Market Cap(Mil.): $202.18
Shares Outstanding(Mil.): 25.12
Dividend: --
Yield (%): --

Financials

  STML.O Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -2.31 -- --
ROI: -50.27 2.29 -5.84
ROE: -50.43 0.06 -5.23

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

May 10 2017

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

Mar 23 2017

BRIEF-Stemline Therapeutics Q4 loss per share $0.56

* Stemline therapeutics reports fourth quarter 2016 financial results

Mar 16 2017

BRIEF-Stemline Therapeutics provides update on pivotal BPDCN trial

* Stemline therapeutics provides update on pivotal bpdcn trial

Feb 02 2017

More From Around the Web

Competitors

Earnings vs. Estimates